Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Two Elan neurology products move closer to market in U.S.

Jan. 12, 1999

Preparation and use of new class of tachykinin antagonists disclosed by MS&D

Jan. 12, 1999

Abbott files for marketing approval of novel ICU sedative and analgesic compound

Jan. 11, 1999

Sibia Neurosciences completes phase I study of SIB-1553A and initiates phase II study

Jan. 11, 1999

Pharmacokinetic profile of edaravone, a novel antioxidant from Mitsubishi Chemical

Jan. 8, 1999

Creative BioMolecules licenses neurotrophic protein from Cambridge NeuroScience

Jan. 8, 1999

Histamine H3 antagonist ciproxifan shows positive behavioral effects in animal models

Jan. 8, 1999

Mexiletine effectively controls spasmodic torticollis in treatment-refractory patients

Jan. 8, 1999

Diatide receives patent protection for novel cancer pain treatment

Jan. 8, 1999

Remacemide provides neuroprotection during CPB

Jan. 7, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...